Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial
作者： Saundra S. Buys , Edward Partridge , Mark H. Greene , Philip C. Prorok , Douglas Reding
DOI: 10.1016/J.AJOG.2005.05.005
关键词:
摘要: Objective Ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 was evaluated in the Prostate, Lung, Colorectal (PLCO) Trial. Study design This a randomized controlled trial of versus usual care. Baseline results are reported. Results Of 39,115 women to receive screening, 28,816 received at least 1 test. Abnormal TVU found 1338 (4.7%), abnormal 402 (1.4%). Twenty-nine neoplasms were identified (26 ovarian, 2 fallopian, primary peritoneal neoplasm). Nine tumors low malignant potential 20 invasive. The positive predictive value for invasive 3.7% an CA-125, 1.0% TVU, 23.5% if both tests abnormal. Conclusion effect on ovarian mortality PLCO cohort has yet be will require longer follow-up. Screening early- late-stage neoplasms, relatively low.
elsevier.com
sci-hub.se 参考文章(20)
Robert E. Scully, Robert C. Bast, Robert C. Knapp, Nina Einhorn, Paul Hall, Vincent R. Zurawski, Kerstin Sjövall, Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstetrics & Gynecology. ,vol. 80, pp. 14- 18 ,(1992)
Antonio D’Aloia, Pompilio Faggiano, Gerard Aurigemma, Luca Bontempi, Giuseppina Ruggeri, Marco Metra, Savina Nodari, Livio Dei Cas, Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis Journal of the American College of Cardiology. ,vol. 41, pp. 1805- 1811 ,(2003) , 10.1016/S0735-1097(03)00311-5
David Haber, Guide to clinical preventive services: a challenge to physician resourcefulness Clinical Gerontologist. ,vol. 12, pp. 17- 29 ,(1993) , 10.1300/J018V12N03_03
Gerardo Zanetta, Sonia Rota, Stefania Chiari, Cristina Bonazzi, Giorgio Bratina, Costantino Mangioni, BEHAVIOR OF BORDERLINE TUMORS WITH PARTICULAR INTEREST TO PERSISTENCE, RECURRENCE, AND PROGRESSION TO INVASIVE CARCINOMA: A PROSPECTIVE STUDY Journal of Clinical Oncology. ,vol. 19, pp. 2658- 2664 ,(2001) , 10.1200/JCO.2001.19.10.2658
A Olaitan, J Weeks, A Mocroft, J Smith, K Howe, J Murdoch, The surgical management of women with ovarian cancer in the south west of England British Journal of Cancer. ,vol. 85, pp. 1824- 1830 ,(2001) , 10.1054/BJOC.2001.2196
Shigemi Sato, Yoshihito Yokoyama, Tomomi Sakamoto, Masayuki Futagami, Yoshiharu Saito, Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer. ,vol. 89, pp. 582- 588 ,(2000) , 10.1002/1097-0142(20000801)89:3<582::AID-CNCR13>3.0.CO;2-#
Philip C Prorok, Gerald L Andriole, Robert S Bresalier, Saundra S Buys, David Chia, E David Crawford, Ronald Fogel, Edward P Gelmann, Fred Gilbert, Marsha A Hasson, Richard B Hayes, Christine Cole Johnson, Jack S Mandel, Albert Oberman, Barbara O'Brien, Martin M Oken, Sameer Rafla, Douglas Reding, Wilmer Rutt, Joel L Weissfeld, Lance Yokochi, John K Gohagan, FACE for the PLCO Project Team, Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial Controlled Clinical Trials. ,vol. 21, pp. 273- ,(2000) , 10.1016/S0197-2456(00)00098-2
Steven J Skates, Usha Menon, Nicola MacDonald, Adam N Rosenthal, David H Oram, Robert C Knapp, Ian J Jacobs, Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women Journal of Clinical Oncology. ,vol. 21, pp. 206- 210 ,(2003) , 10.1200/JCO.2003.02.955
E. J. Junor, D. J. Hole, L. McNulty, M. Mason, J. Young, Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. British Journal of Obstetrics and Gynaecology. ,vol. 106, pp. 1130- 1136 ,(1999) , 10.1111/J.1471-0528.1999.TB08137.X
J.R. van Nagell, P.D. DePriest, M.B. Reedy, H.H. Gallion, F.R. Ueland, E.J. Pavlik, R.J. Kryscio, The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecologic Oncology. ,vol. 77, pp. 350- 356 ,(2000) , 10.1006/GYNO.2000.5816